Home - Belmore Neidrauer LLP

Persuasive Advocacy.
Proven Results.

We are experts in intellectual property litigation. We are trial lawyers.
We are appellate lawyers. We know patent law, inside and out.
Learn More

News

LEXPERT® recognizes Marian Wolanski!

This recognition as one of the Consistently Recommended lawyers for Intellectual Property Litigation is a testament to the depth of talent at Belmore Neidrauer and reflects the firm’s status as a leading law firm for IP litigation in Canada.
Chambers Patent Litigation 2026

Belmore Neidrauer is proud to be a contributor to Chambers Patent Litigation 2026! The guide provides information on IP rights and granting procedures, initiating a patent infringement lawsuit, patent revocation/cancellation, patent remedies, litigation costs, alternative dispute resolution (ADR), and assignment and licensing of IP rights.
Belmore Neidrauer Recognized by Managing IP!

Belmore Neidrauer is pleased to announce partner Marian Wolanski has been shortlisted for Practitioner of the Year (Patent Disputes) – Canada at the upcoming 2026 Managing IP Americas Awards!
The 18th Annual Harold G. Fox Moot

Belmore Neidrauer is pleased to sponsor the Harold G. Fox Moot once again! Marian Wolanski and Megan Pocalyuko are looking forward to volunteering as panel judges this year. Best of luck to all mooters!
Belmore Neidrauer Recognized by Chambers and Partners

Belmore Neidrauer is delighted to be ranked in the Chambers Global 2026 guide for IP Litigation, with Partner Marian Wolanski also being included in the lawyer rankings.
Marian Wolanski will be speaking at the 14th Annual University of Toronto Patent Colloquium!

Event Details: 14th Annual University of Toronto Patent Colloquium

Our Team

Equipped with a Master’s degree in Medical Sciences, Oleyna is a fierce advocate known for her drive and tenacity.
Oleyna Strigul

Associate

p.(416) 863-3356

f.(416) 863-9171

e.ostrigul@belmorelaw.com

See The Full Team

Our cases

September 04, 2025

Alexion Pharmaceuticals v Amgen Canada

Counsel: Marian Wolanski and Megan Pocalyuko

Belmore Neidrauer along with co-counsel was presented with the LMG Impact Case of the Year – Canada award for our work on Alexion v Amgen (2025 FC 754).
Read more
October 02, 2025

Samsung Bioepis Co. Ltd. v Janssen Biotech, Inc.

Counsel: Marian Wolanski, Heather Lindsay and Oleyna Strigul

We represented Janssen. This case related to Janssen’s patent covering its blockbuster drug STELARA. The notice of discontinuance was filed October 2, 2025
Read more
July 18, 2025

Janssen Inc. v Apotex

Counsel: Marian Wolanski, Megan Pocalyuko and Heather Lindsay

We represented Janssen. This action related to Mitsubishi’s 357 patent covering the diabetes drug INVOKANA. This action was discontinued July 2025.
Read more
May 13, 2025

Pharmascience v. Janssen

Counsel: Marian Wolanski and Heather Lindsay

We represented Janssen. This was an action for damages under section 8 of the Patented Medicines Notice of Compliance Regulations relating to abiraterone acetate. The action was discontinued shortly before trial (May 2025).
Read more
April 25, 2025

Janssen Inc. v JAMP

Counsel: Marian Wolanski, Megan Pocalyuko and Heather Lindsay

We represented Janssen. This action related to Janssen’s 024 Patent covering the diabetes drug INVOKANA. The action was discontinued in April 2025.
Read more
February 16, 2024

Janssen Inc. v Pharmascience Inc.

Counsel: Marian Wolanski, Megan Pocalyuko and Oleyna Strigul

Belmore Neidrauer secured another victory in the Federal Court of Appeal for our client Janssen relating to the validity of Janssen’s patent covering INVEGA SUSTENNA®
Read more
January 12, 2024

Janssen Inc. v Apotex Inc.

Counsel: Marian Wolanski, Megan Pocalyuko and Oleyna Strigul

We successfully represented Janssen on another appeal relating to infringement of Janssen’s patent covering INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia.
Read more
January 12, 2024

Janssen v. Pharmascience

Counsel: Marian Wolanski, Megan Pocalyuko and Oleyna Strigul

We successfully represented Janssen in the Federal Court of Appeal on this appeal relating to infringement of the patent covering Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia.
Read more
December 22, 2023

Janssen Inc. v Apotex Inc.

Counsel: Marian Wolanski, Megan Pocalyuko and Oleyna Strigul

Belmore Neidrauer has successfully represented Janssen on another appeal, resulting in a decision overturning the Federal Court’s denial of summary judgment.
Read more
March 23, 2023

Janssen Inc. et al v. Teva Canada Limited

Counsel: Marian Wolanski and Megan Pocalyuko

We successfully represented Janssen on Teva’s appeal and Janssen’s cross-appeal in a significant decision relating to the law of inducing patent infringement in Canada. The decision relates to Janssen’s patent covering INVEGA SUSTENNA® (paliperidone ...
Read more
October 27, 2022

Janssen v. Apotex

We successfully represented Janssen in a motion to appeal an order of the Associate Judge which declined, based on relevance, to compel Apotex to answer certain discovery questions related to its ability to supply its generic abiraterone acetate prod...
Read more
October 27, 2022

Janssen v. Apotex

We successfully represented Janssen in a motion to Amend its Statement of Defence in this PMNOC section 8 damages action. The Court agreed that Janssen was allowed to amend its Statement of Defence to raise issues as to Apotex’s ability to supply the...
Read more
December 05, 2022

Janssen v. Dr. Reddy

We successfully represented Janssen in this motion brought by Dr. Reddy’s in the context of a PMNOC section 8 damages action. Dr. Reddy’s was seeking to have a question of law determined before trial. The question of law related to whether Janssen co...
Read more
January 19, 2023

Janssen v. Pharmascience

Counsel: Marian Wolanski

We successfully represented Janssen in a motion brought by the appellant (Pharmascience) to settle the contents of the appeal book in the context of an appeal from the judgment of the Federal Court in Janssen Inc. v. Pharmascience Inc., 2022 FC 1218 ...
Read more
January 24, 2023

Alexion v. Attorney General of Canada

Counsel: Marian Wolanski

This was an application to add an inventor to two patents owned by Alexion Pharmaceuticals. The patents relate to Alexion’s blockbuster drug SOLIRIS. The application was granted, ensuring that the correct inventors are named on the patents relating t...
Read more
February 14, 2023

Apotex Inc. v Janssen Inc. et al

Counsel: Heather Lindsay

We successfully represented Janssen on these motions seeking non-party discovery in three PMNOC section 8 actions.Each of Apotex, Dr. Reddy’s and Pharmascience resisted, on numerous grounds, non-party discovery for use in these section 8 actions. The...
Read more
August 23, 2022

Janssen v. Pharmascience

Counsel: Marian Wolanski, Megan Pocalyuko and Oleyna Strigul

We successfully represented Janssen in defending the validity of the patent relating to Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product used to treat schizophrenia.
Read more
January 31, 2022

Janssen v Apotex

Counsel: Marian Wolanski and Megan Pocalyuko

We successfully represented Janssen in this summary trial in the Federal Court on infringement issues against Apotex in respect of Janssen’s patent covering its important INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product used t...
Read more
January 19, 2022

Janssen v Pharmascience

Counsel: Marian Wolanski and Megan Pocalyuko

We successfully represented Janssen in this summary trial in the Federal Court on infringement issues against Pharmascience in respect of Janssen’s patent covering its important INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product...
Read more
January 14, 2021

Janssen v Apotex, Pharmascience and Dr. Reddy’s Laboratories

Counsel: Marian Wolanski and Megan Pocalyuko

We represented Janssen and BTG in these patent infringement actions relating to Janssen’s prostate cancer product ZYTIGA®(abiraterone acetate). We were successful in proving inducing infringement and in resisting the defendants’ attacks based on lack...
Read more

See all cases

Awards

Consistently Recognized
for Excellence.

We are consistently recognized as leading IP litigators in Canada. Among others, we are recognized by:

IAM Patent 1000 Recognized for Patent Litigation 2026
Chambers Global Recognized for Intellectual Property: Litigation 2026
Legal 500 Canada Elite Boutique 2026
Best Law Firms - Canada Tier 1 for Intellectual Property Law 2026
Chambers Recognized for Intellectual Property: Litigation 2026
LMG Life Science Recommended for Patent Litigation (Branded) 2025
IAM Patent 1000 Recognized for Patent Litigation 2025
Legal 500 Canada Elite Boutique 2025

See all awards

Persuasive Advocacy.Proven Results.

News

Our Team

Our cases

Awards

Consistently Recognizedfor Excellence.

Persuasive Advocacy.
Proven Results.

Consistently Recognized
for Excellence.